Recombinant Candida dubliniensis Formation of crista junctions protein 1 (FCJ1)

What is Candida dubliniensis and why is it significant in research?

Candida dubliniensis is a recently described yeast species that was first isolated from AIDS patients in Dublin, Ireland. It is closely related to C. albicans but represents a distinct species with unique phenotypic and genotypic characteristics. The significance of C. dubliniensis lies in its emergence as an opportunistic pathogen, particularly in HIV-infected individuals and AIDS patients, with the potential to cause invasive disease including bloodstream infections .

The organism has been recovered from patients in widespread geographic locations, with incidence data showing it can be isolated from 27% of HIV-infected individuals and 32% of AIDS patients with clinical symptoms of oral candidiasis . Its clinical importance is further highlighted by its ability to develop resistance to fluconazole, a commonly used antifungal drug, particularly in HIV-positive patients .

Research on C. dubliniensis proteins, including FCJ1, is valuable for understanding pathogen biology, developing diagnostic tools, and potentially identifying novel therapeutic targets.

What is the FCJ1 protein and what is its biological function?

Formation of crista junctions protein 1 (FCJ1), also known as MIC60 or Mitofilin, is a mitochondrial protein that forms part of the MICOS complex (Mitochondrial Contact Site and Cristae Organizing System) . The protein plays a critical role in:

• Maintaining mitochondrial inner membrane architecture

• Formation and stabilization of crista junctions

• Organizing contact sites between the inner and outer mitochondrial membranes

• Supporting mitochondrial protein import and respiratory chain assembly

In C. dubliniensis, the mature FCJ1 protein spans amino acids 18-564, containing regions essential for membrane association and protein-protein interactions . Its function is inferred from homologous proteins in other fungi, particularly Saccharomyces cerevisiae, where FCJ1/Mic60 disruption leads to abnormal cristae morphology and compromised mitochondrial function.

How does recombinant C. dubliniensis FCJ1 differ from the native protein?

The recombinant C. dubliniensis FCJ1 protein differs from the native form in several important aspects:

These differences must be considered when designing experiments and interpreting results, as they may affect protein activity, binding properties, and structural studies.

What are the optimal conditions for handling recombinant C. dubliniensis FCJ1 protein?

For optimal handling of recombinant C. dubliniensis FCJ1 protein, researchers should follow these evidence-based guidelines:

• Storage:

  • Store lyophilized protein at -20°C to -80°C upon receipt

  • Aliquot reconstituted protein to avoid repeated freeze-thaw cycles

  • Working aliquots can be stored at 4°C for up to one week

• Reconstitution:

  • Briefly centrifuge vial before opening

  • Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

  • Add glycerol to a final concentration of 5-50% (recommended 50%) for long-term storage

• Buffer conditions:

  • Standard storage in Tris/PBS-based buffer, pH 8.0, containing 6% trehalose

  • For functional assays, verify compatibility with specific buffer requirements

• Stability considerations:

  • Avoid repeated freeze-thaw cycles as they may cause protein denaturation

  • Monitor protein integrity through SDS-PAGE or size exclusion chromatography

Following these guidelines will help maintain protein integrity and functionality for experimental applications.

How can researchers verify the identity and purity of recombinant C. dubliniensis FCJ1?

Verification of recombinant C. dubliniensis FCJ1 identity and purity requires multiple complementary approaches:

• SDS-PAGE analysis:

  • Expected molecular weight: ~60-65 kDa (including His-tag)

  • Purity should exceed 90% as determined by densitometry

• Western blotting:

  • Primary detection: anti-His antibodies to detect the N-terminal tag

  • Secondary verification: FCJ1/MIC60-specific antibodies (if available)

• Mass spectrometry:

  • Peptide mass fingerprinting for sequence verification

  • Coverage should include unique peptides distinguishing FCJ1 from homologous proteins

• Functional assays:

  • Membrane binding capacity

  • Protein-protein interaction studies with other MICOS components

• N-terminal sequencing:

  • Confirmation of correct processing (starting at amino acid 18)

  • Verification of His-tag presence

A comprehensive verification protocol should include at least three of these methods to ensure confidence in protein identity and purity.

What experimental systems are suitable for studying C. dubliniensis FCJ1 function?

Several experimental systems can effectively study C. dubliniensis FCJ1 function, each with specific advantages:

• In vitro reconstitution systems:

  • Liposome incorporation to study membrane interactions

  • Reconstitution with other MICOS components to assess complex formation

  • Advantages: Controlled environment, direct measurement of biochemical properties

• Heterologous expression in model fungi:

  • FCJ1/MIC60 knockout strains of S. cerevisiae complemented with C. dubliniensis FCJ1

  • Advantages: Assessment of in vivo function, mitochondrial phenotype rescue

• C. dubliniensis genetic modification:

  • CRISPR/Cas9-mediated gene editing to create FCJ1 mutants

  • Conditional expression systems to study FCJ1 depletion effects

  • Advantages: Native context, relevance to pathogen biology

• Mammalian cell culture models:

  • Expression in mammalian cells to study interspecies compatibility

  • Localization studies and effects on host mitochondria

  • Advantages: Relevance to host-pathogen interactions

• Biophysical approaches:

  • Structural studies (X-ray crystallography, cryo-EM)

  • Dynamic studies using FRET or other fluorescence techniques

  • Advantages: Detailed molecular information on protein structure and interactions

Selection of the appropriate system depends on the specific research question, available resources, and technical expertise.

How does C. dubliniensis FCJ1 compare to homologous proteins in C. albicans and other fungi?

The C. dubliniensis FCJ1 protein shares significant sequence and functional homology with related proteins in other fungi, particularly C. albicans, but with distinct characteristics:

These comparisons are relevant because C. dubliniensis is frequently misidentified as C. albicans due to their phenotypic similarities . The specific differences in FCJ1 and other proteins may contribute to the distinct pathogenic profiles of these species, particularly in terms of their prevalence in different patient populations and their susceptibility to antifungal drugs .

Understanding these differences is critical for:

• Developing species-specific diagnostic methods

• Investigating potential species-specific drug targets

• Elucidating the evolutionary history of mitochondrial architecture in pathogenic fungi

What is the relationship between FCJ1 dysfunction and C. dubliniensis pathogenicity?

The relationship between FCJ1 dysfunction and C. dubliniensis pathogenicity represents an emerging area of research with several hypothesized connections:

• Metabolic adaptation: Mitochondrial function, including proper cristae organization maintained by FCJ1, is critical for metabolic flexibility during host colonization and infection. Dysfunction may alter the ability of C. dubliniensis to adapt to different nutrient environments encountered during infection.

• Stress response: Proper mitochondrial function is essential for responding to oxidative stress, which is a key host defense mechanism. FCJ1 dysfunction could potentially alter susceptibility to host-derived reactive oxygen species.

• Morphogenesis regulation: In C. albicans and potentially C. dubliniensis, mitochondrial function influences the yeast-to-hyphal transition, which is associated with virulence. FCJ1 dysfunction may affect this morphological switching.

• Antifungal susceptibility: Mitochondrial proteins have been implicated in resistance to azole antifungals, which is particularly relevant given C. dubliniensis' ability to rapidly develop fluconazole resistance . FCJ1 dysfunction might contribute to altered drug susceptibility profiles.

While direct evidence linking FCJ1 to C. dubliniensis pathogenicity is limited in the current literature, these potential connections warrant further investigation, particularly given the clinical importance of understanding mechanisms underlying the emergence of this opportunistic pathogen in immunocompromised populations .

What are the challenges in expressing and purifying functional recombinant C. dubliniensis FCJ1?

Expression and purification of functional recombinant C. dubliniensis FCJ1 presents several technical challenges:

• Membrane protein solubility:

  • FCJ1 naturally associates with mitochondrial membranes

  • Expression in E. coli often leads to inclusion body formation

  • Solution: Optimize solubilization conditions or use specialized membrane protein expression systems

• Proper folding:

  • Eukaryotic protein expressed in prokaryotic system lacks appropriate chaperones

  • Potential misfolding affects functional studies

  • Solution: Consider expression in eukaryotic systems (yeast, insect cells) or refolding protocols

• Post-translational modifications:

  • Fungal-specific modifications absent in E. coli expression

  • May affect protein-protein interactions and function

  • Solution: Expression in yeast systems closer to native environment

• Protein stability:

  • Tendency to aggregate when removed from membrane environment

  • Challenge for long-term storage and functional assays

  • Solution: Optimize buffer conditions with appropriate detergents or membrane mimetics

• Functional verification:

  • Lack of simple activity assays for structural proteins like FCJ1

  • Difficult to confirm if recombinant protein retains native function

  • Solution: Develop interaction assays with known binding partners

Addressing these challenges requires systematic optimization of expression conditions, purification protocols, and functional characterization approaches to ensure that the recombinant protein adequately represents the native FCJ1 for research applications.

How can researchers use recombinant FCJ1 to develop diagnostic tools for C. dubliniensis?

Recombinant C. dubliniensis FCJ1 protein offers several avenues for developing improved diagnostic tools to address the challenge of distinguishing C. dubliniensis from C. albicans :

• Antibody-based detection systems:

  • Generate FCJ1-specific antibodies targeting unique epitopes

  • Develop ELISA or lateral flow assays for clinical samples

  • Implementation strategy: Map epitopes unique to C. dubliniensis FCJ1 not present in C. albicans homolog

• Mass spectrometry identification markers:

  • Identify FCJ1-derived peptides as species-specific biomarkers

  • Incorporate into existing clinical MS platforms

  • Validation approach: Test against diverse clinical isolates to confirm specificity

• Aptamer-based detection:

  • Select DNA/RNA aptamers with specificity for C. dubliniensis FCJ1

  • Develop aptamer-based biosensors for rapid detection

  • Optimization focus: Minimize cross-reactivity with C. albicans proteins

• Functional screening assays:

  • Exploit biochemical differences between C. dubliniensis and C. albicans FCJ1

  • Develop activity-based probes for specific detection

  • Challenge: Identifying functional differences amenable to assay development

Current diagnostic challenges include the phenotypic similarity between C. dubliniensis and C. albicans, with studies showing that approximately 2% of isolates from healthy individuals and 17% of isolates from HIV-infected individuals originally identified as C. albicans were actually C. dubliniensis . Improved diagnostics would address this significant clinical challenge and enhance epidemiological surveillance, which is particularly important given C. dubliniensis' association with fluconazole resistance .

What are the recommended experimental controls when working with recombinant C. dubliniensis FCJ1?

Rigorous experimental design for recombinant C. dubliniensis FCJ1 research requires appropriate controls:

• Protein quality controls:

  • Negative control: Buffer-only conditions to assess background signals

  • Positive control: Commercial His-tagged protein of similar size/structure

  • Stability control: Time-course analysis of protein under experimental conditions

• Species-specificity controls:

  • C. albicans FCJ1 homolog to assess cross-reactivity

  • Other Candida species FCJ1 proteins for comparative analyses

  • Implementation: Include in binding studies, immunological assays, and functional tests

• Functional controls:

  • Denatured FCJ1 to distinguish specific vs. non-specific interactions

  • FCJ1 mutants with altered functional domains

  • Verification method: Parallel testing under identical conditions

• Expression system controls:

  • E. coli host cell lysate without FCJ1 expression

  • Non-specific His-tagged protein to control for tag effects

  • Analysis approach: Subtract background signals in quantitative assays

• Application-specific controls:

  • For structural studies: Well-characterized protein standards

  • For interaction studies: Known binding and non-binding partners

  • For immunological assays: Pre-immune serum and isotype controls

Implementation of these controls enhances result reliability and facilitates troubleshooting when unexpected outcomes occur.

What methods can be used to study protein-protein interactions involving C. dubliniensis FCJ1?

Multiple complementary approaches can effectively investigate protein-protein interactions involving C. dubliniensis FCJ1:

• Co-immunoprecipitation (Co-IP):

  • Leverage His-tag for pulldown experiments

  • Verify interactions with putative MICOS complex components

  • Strengths: Relatively straightforward, can detect native complexes

  • Limitations: May not detect weak or transient interactions

• Yeast Two-Hybrid (Y2H):

  • Screen for novel interaction partners

  • Map interaction domains through truncation constructs

  • Strengths: High-throughput capability, in vivo context

  • Limitations: High false positive rate, nuclear localization requirement

• Surface Plasmon Resonance (SPR):

  • Quantitative measurement of binding kinetics

  • Determine affinity constants for FCJ1 interactions

  • Strengths: Real-time analysis, label-free detection

  • Limitations: Requires protein immobilization, potential surface effects

• Proximity-based labeling:

  • BioID or APEX2 fusion to FCJ1 for in vivo interaction mapping

  • Identify proximity partners in native context

  • Strengths: Captures transient interactions, works in native environment

  • Limitations: Identifies proximity not necessarily direct interaction

• Crosslinking Mass Spectrometry (XL-MS):

  • Map interaction interfaces at amino acid resolution

  • Identify structural constraints for modeling

  • Strengths: Detailed structural information, captures transient interactions

  • Limitations: Technical complexity, data analysis challenges

Selection of appropriate methods should be guided by specific research questions, available resources, and required level of detail.

How can researchers distinguish between direct and indirect effects of FCJ1 on mitochondrial function?

Distinguishing between direct and indirect effects of FCJ1 on mitochondrial function requires a multi-faceted experimental approach:

• Structure-function analysis:

  • Generate targeted mutations in specific FCJ1 domains

  • Assess effects on distinct mitochondrial parameters

  • Analysis strategy: Identify separable functions through domain-specific mutations

• Temporal control systems:

  • Implement rapid protein depletion methods (e.g., auxin-inducible degron)

  • Monitor time-course of effects following FCJ1 depletion

  • Interpretation framework: Immediate effects (0-30 minutes) likely direct; delayed effects (hours-days) likely indirect

• Biochemical reconstitution:

  • Purified component systems with defined composition

  • Systematic addition/removal of interaction partners

  • Validation approach: Confirm in vitro observations in cellular context

• Proximity-restricted enzyme complementation:

  • Split enzyme reporters fused to FCJ1 and potential targets

  • Spatial restriction of functional readouts

  • Application: Distinguishes effects based on physical proximity

• Comparative systems analysis:

  • Parallel studies in different fungi with conserved and divergent FCJ1 functions

  • Correlation of sequence variation with functional differences

  • Analytical focus: Identify conserved direct functions vs. species-specific indirect effects

How should researchers interpret contradictory results from different FCJ1 functional assays?

When faced with contradictory results from different FCJ1 functional assays, researchers should implement a systematic approach to resolution:

• Technical validation:

  • Verify protein quality and experimental conditions

  • Implement additional controls to identify artifacts

  • Perform independent replication with protocol modifications

• Context-dependent analysis:

  • Assess if contradictions reflect different experimental contexts

  • Consider buffer conditions, protein tags, expression systems

  • Systematically test variable parameters to identify critical factors

• Integration framework:

  • Develop a hierarchical model of evidence reliability

  • Weight results based on methodological strengths/limitations

  • Construct testable hypotheses to explain apparent contradictions

• Resolution strategy matrix:

• Collaborative validation:

  • Engage independent laboratories for confirmation

  • Implement standardized protocols across research groups

  • Conduct blind analysis of shared samples

This approach acknowledges that contradictory results often reflect biological complexity rather than experimental error, potentially revealing important insights about context-dependent FCJ1 functions.

What statistical approaches are most appropriate for analyzing FCJ1 interaction data?

Analysis of FCJ1 interaction data requires appropriate statistical frameworks tailored to the experimental approach:

• For high-throughput screening data:

  • False Discovery Rate (FDR) control for multiple testing

  • Bayesian scoring methods to rank interaction confidence

  • Implementation: Calculate q-values and interaction confidence scores

  • Example application: Yeast two-hybrid or mass spectrometry interaction screens

• For quantitative binding assays:

  • Non-linear regression for binding kinetics

  • Statistical comparison of fitted parameters (Kd, Bmax)

  • Implementation: F-test for model comparison, extra sum-of-squares F test

  • Example application: Surface plasmon resonance or microscale thermophoresis

• For co-localization studies:

  • Spatial statistics (Manders' coefficient, Pearson's correlation)

  • Randomization tests to establish significance thresholds

  • Implementation: Compare observed vs. randomized distribution

  • Example application: Fluorescence microscopy of FCJ1 with binding partners

• For comparative interaction studies:

  • ANOVA with post-hoc testing for multiple conditions

  • Paired analyses for before/after comparisons

  • Implementation: Tukey's HSD for all pairwise comparisons

  • Example application: Comparing FCJ1 interactome across conditions

• For systems-level network analysis:

  • Graph theory metrics (betweenness centrality, clustering)

  • Enrichment analysis for functional interpretation

  • Implementation: Comparison to random networks, GO term enrichment

  • Example application: Integrating FCJ1 into mitochondrial protein interaction networks